Experimental gene therapy CTx1000 extends survival in mice
An experimental gene therapy called CTx1000, which is designed to reduce toxic buildups of the protein TDP-43 in nerve cells,…
Articles by Marisa Wexler, MS
Potential ALS treatment ATH-1105 due to enter clinical testing this year
Treatment with the experimental oral therapy ATH-1105 significantly reduced nerve damage, improved motor function, and prolonged survival in…
Blocking MAP4Ks proteins extends survival in ALS mouse model
A new compound that significantly extended survival in a mouse model of amyotrophic lateral sclerosis (ALS)…
TDP-43 deficiency leads to changes in physical structures of cell DNA
Reduced activity of the TDP-43 protein, a hallmark of amyotrophic lateral sclerosis (ALS), leads to changes in the DNA…
Novel AI-powered platform aims to help ALS patients to communicate
Researchers have unveiled a new AI-powered avatar platform — one making use of artificial intelligence (AI) technology — that aims…
Scientists ID site in motor neurons where ALS dysfunction may start
Scientists at King’s College London have identified the site in motor neurons that appears to be the starting point of…
ALS/MND 2023: AMX0114 may enter clinical testing next year
Amylyx Pharmaceuticals is developing AMX0114, a new experimental treatment for amyotrophic lateral sclerosis (ALS) that’s designed to promote…
Changes in speech with ALS to be monitored in planned Phase 1b trial
A Phase 1b proof-of-concept clinical trial of the experimental oral therapy VRG50635 in people with amyotrophic lateral sclerosis (ALS)…
‘Molecular traps’ may help fend off nerve damage from gene mutations
Scientists have created new “molecular traps” that were able to improve survival in cell and fruit fly models of…
Implant may help patients to speak by decoding their thoughts better
A new advance in technology may pave the way for devices that could allow people with amyotrophic lateral sclerosis…